Physician profile
Bryan Waits
NPI 1891952917
$4,821.25
in general payments reported to CMS, 2019-2025
26 companies · $285 in 2025
The $285 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $578 · 2020: $842 · 2021: $774 · 2022: $1,505 · 2023: $353 · 2024: $485 · 2025: $285.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,122.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,579.36 | 2021-2024 | Onyx Frontier, Corevalve Evolut R, Hawkone |
| Abbott Laboratories | $588.28 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $475.48 | 2020-2023 | Xarelto |
| Medtronic Vascular, INC. | $348.54 | 2020 | |
| Novartis Pharmaceuticals Corporation | $333.97 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $207.87 | 2019-2025 | Lifevest |
| Biotronik INC. | $167.96 | 2019-2021 | |
| Edwards Lifesciences Corporation | $112.11 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Novo Nordisk INC | $109.45 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Stryker Corporation | $105.46 | 2025 | Artix Mt |
| E.R. Squibb & Sons, L.L.C. | $99.12 | 2019-2023 | Camzyos |
| Boston Scientific Corporation | $91.87 | 2019-2025 | Watchman Flx |
| Amgen INC. | $88.51 | 2019-2025 | Repatha |
| Abiomed | $79.68 | 2023-2024 | Impella |
| Actelion Pharmaceuticals US, INC. | $69.41 | 2020-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $61.02 | 2022-2023 | |
| Sanofi-Aventis U.S. LLC | $60.85 | 2023 | |
| Acist Medical Systems, INC. | $54.00 | 2021 | |
| Tactile Systems Technology INC | $40.13 | 2019-2024 | Flexitouch Plus, Entre Plus |
| Astrazeneca Pharmaceuticals LP | $27.97 | 2020-2024 | Farxiga |
| Kestra Medical Technology Services, INC. | $24.92 | 2023 | Assure Wcd |
| Amarin Pharma, INC. | $24.87 | 2021 | |
| Alexion Pharmaceuticals, INC. | $21.78 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.13 | 2021 | |
| Cardiovascular Systems INC. | $15.59 | 2020-2021 | |
| Gilead Sciences, INC. | $11.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Waits listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.